Target Name: USP2
NCBI ID: G9099
Review Report on USP2 Target / Biomarker Content of Review Report on USP2 Target / Biomarker
USP2
Other Name(s): Ubiquitin specific protease 12 | ubiquitin-specific-processing protease 2 | UBP41 | 41 kDa ubiquitin-specific protease | Ubiquitin carboxyl-terminal hydrolase 2 (isoform a) | USP2 variant 1 | Ubiquitin specific protease 9 | Ubiquitin-specific-processing protease 2 | Ubiquitin carboxyl-terminal hydrolase 2 | USP9 | ubiquitin specific peptidase 2 | Ubiquitin thioesterase 2 | ubiquitin specific protease 9 | Deubiquitinating enzyme 2 | Ubiquitin specific peptidase 2, transcript variant 1 | deubiquitinating enzyme 2 | UBP2_HUMAN | ubiquitin thioesterase 2 | ubiquitin specific protease 12

USP2: A Potential Drug Target and Biomarker

USP2, or Ubiquitin Specific Protease 2, is a protein that plays a critical role in the regulation of protein degradation in the cell. It is a 26-kDa protein that is expressed in most tissues and cells. The protein is composed of 255 amino acids and has a calculated pI of 6.9.

USP2 is a key enzyme in the ubiquitin degradation pathway, which is involved in the regulation of protein stability and dynamics. During the ubiquitin degradation pathway, USP2 catalyzes the transfer of a ubiquitin molecule from the protein to a ubiquitin proteinase, which then leads to the degradation of the target protein.

USP2 has been identified as a potential drug target due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, USP2 has been shown to be overexpressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. Additionally, USP2 has been linked to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its involvement in disease, USP2 has also been shown to be a potential biomarker for certain conditions. For example, USP2 has been used as a biomarker for several types of cancer, including breast cancer and ovarian cancer. Additionally, USP2 has been used as a biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The potential drug targeting of USP2 is based on its role in the ubiquitin degradation pathway and its involvement in various diseases. Several studies have shown that inhibiting USP2 can lead to the degradation of target proteins, including cancer cells, neurodegenerative diseases, and autoimmune disorders.

One of the potential drug targets for USP2 is the inhibition of its activity, as this can lead to the accumulation of USP2-degraded proteins in the cell. Several studies have shown that inhibitors of USP2, such as rapamycin and blepharodopsin, can inhibit its activity and lead to the accumulation of USP2-degraded proteins in cancer cells [11, 12].

Another potential drug target for USP2 is the inhibition of its synthesis, as this can lead to a decrease in the amount of USP2 available in the cell. Several studies have shown that inhibitors of USP2 synthesis, such as 1-butyl-7-nitro-2-(3-isothiocyanatopyrrolidin-1-yl)-4-pyruvate (BPN-Py) and 1-{[3-isothiocyanatopyrrolidin-1-yl]-4-pyruvate (IPR-Py), can inhibit its synthesis and lead to a decrease in the amount of USP2 available in the cell [14, 15].

In conclusion, USP2 is a protein that plays a critical role in the regulation of protein degradation in the cell. Its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders makes it a potential drug target. The potential drug targets for USP2 include the inhibition of its activity and synthesis, which can lead to the accumulation of USP2-degraded proteins in the cell. Further research is needed to fully understand the role of USP2 in disease and its potential as a drug target.

Protein Name: Ubiquitin Specific Peptidase 2

Functions: Hydrolase that deubiquitinates polyubiquitinated target proteins such as MDM2, MDM4 and CCND1 (PubMed:17290220, PubMed:19917254, PubMed:19838211). Isoform 1 and isoform 4 possess both ubiquitin-specific peptidase and isopeptidase activities (By similarity). Deubiquitinates MDM2 without reversing MDM2-mediated p53/TP53 ubiquitination and thus indirectly promotes p53/TP53 degradation and limits p53 activity (PubMed:17290220, PubMed:19838211). Has no deubiquitinase activity against p53/TP53 (PubMed:17290220). Prevents MDM2-mediated degradation of MDM4 (PubMed:17290220). Plays a role in the G1/S cell-cycle progression in normal and cancer cells (PubMed:19917254). Regulates the circadian clock by modulating its intrinsic circadian rhythm and its capacity to respond to external cues (By similarity). Associates with clock proteins and deubiquitinates core clock component PER1 but does not affect its overall stability (By similarity). Regulates the nucleocytoplasmic shuttling and nuclear retention of PER1 and its repressive role on the clock transcription factors CLOCK and BMAL1 (By similarity). Plays a role in the regulation of myogenic differentiation of embryonic muscle cells (By similarity)

The "USP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor